Faculty

Connie Celum

Adjunct Professor, Epidemiology
Professor, Global Health
Professor, Medicine - Allergy and Infectious Dis.


Education

MD Medicine, University of California (San Francisco), 1984
MPH Epidemiology, University of Washington, 1989

Contact


Box 359927
University of Washington
Seattle, WA
University of Washington
Box 359927
Allergy and Infectious Diseases
Seattle, WA 98195

Research Interests

Dr. Celum's research currently focuses on HIV prevention and vaccine trials with the objective to find effective strategies to reduce HIV acquisition and transmission. She utilizes epidemiologic data on behavioral and biologic risk factors for HIV acquisition and transmission to identify potential intervention strategies and then to conduct randomized clinical trials to determine safety and efficacy of these interventions with biologic outcome measurements. Her current effort is focused on sexually transmitted diseases (STDs), particularly genital herpes, as co-factors for HIV acquisition and transmission and clinical trials of candidate HIV vaccines. First, she is investigating HSV-2 as a co-factor for HIV acquisition and transmission, through a large randomized trial of daily antivirals for HSV-2 suppression to determine whether HIV acquisition can be reduced by 50% among HIV-negative, HSV-2 seropositive women in two African sites, and among MSM in Peru and two US sites. Second, to determine the effect of genital herpes on HIV infectiousness, she is conducting a large multi-center trial of HSV-2 suppression among HIV-discordant couples in Africa and India. Third, she is studying the effect of HSV-2 on mucosal HIV shedding with a double-blind cross-over study of valacyclovir among HIV/HSV-2 co-infected men and women in Peru. Fourth, she is studying the prevalence, incidence and risk factors for HSV-1 and HSV-2 acquisition among high-risk men who have sex with men in a multi-center trial of a behavioral intervention (Project Explore). Fifth, as part of her interest in the evaluation of HIV vaccine trials, she is developing approaches to assess the effect of partially-effective HIV vaccines on viral set-point and disease progression, including a standardized approach to provision of antiretroviral therapy for breakthrough infections in phase III trials.

Dr. Celum has developed research clinical units in Seattle and Lima, Peru, to conduct epidemiologic studies and clinical trials of HIV prevention interventions and vaccines. In addition, she serves as the PI on two multi-center international clinical trials of HSV-2 suppression and HIV transmission with sites in Africa, India, and Latin America, which provide opportunities for graduate students interested in studying the epidemiology of STD and HIV infection

HIV prevention; microbicide; vaccine trials with the objective to find effective strategies to reduce HIV acquisition and transmission.

Recent Publications (PubMed)

Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity.
(2022 Jan 4)
JAMA Netw Open 5(1): e2142796
Stankiewicz Karita HC, Dong TQ, Johnston C, Neuzil KM, Paasche-Orlow MK, Kissinger PJ, Bershteyn A, Thorpe LE, Deming M, Kottkamp A, Laufer M, Landovitz RJ, Luk A, Hoffman R, Roychoudhury P, Magaret CA, Greninger AL, Huang ML, Jerome KR, Wener M, Celum C, Chu HY, Baeten JM, Wald A, Barnabas RV, Brown ER

Mycobacterium tuberculosis-specific T cell responses are impaired during late pregnancy with elevated biomarkers of tuberculosis risk postpartum.
(2021 Dec 20)
J Infect Dis
Saha A, Escudero J, Layouni T, Richardson B, Hou S, Mugo N, Mujugira A, Celum C, Baeten JM, Lingappa J, John-Stewart GC, LaCourse SM, Shah JA

Adolescent girls and young women's PrEP-user journey during an implementation science study in South Africa and Kenya.
(2021)
PLoS One 16(10): e0258542
Rousseau E, Katz AWK, O'Rourke S, Bekker LG, Delany-Moretlwe S, Bukusi E, Travill D, Omollo V, Morton JF, O'Malley G, Haberer JE, Heffron R, Johnson R, Celum C, Baeten JM, van der Straten A

How community ART delivery may improve HIV treatment outcomes: Qualitative inquiry into mechanisms of effect in a randomized trial of community-based ART initiation, monitoring and re-supply (DO ART) in South Africa and Uganda.
(2021 Oct)
J Int AIDS Soc 24(10): e25821
Gilbert HN, Wyatt MA, Pisarski EE, Asiimwe S, van Rooyen H, Seeley J, Shahmanesh M, Turyamureeba B, van Heerden A, Adeagbo O, Celum CL, Barnabas RV, Ware NC, Delivery Optimization of Antiretroviral Therapy (DO ART) Study Team.

Simplifying TREAtment and Monitoring for HIV (STREAM HIV): protocol for a randomised controlled trial of point-of-care urine tenofovir and viral load testing to improve HIV outcomes.
(2021 Oct 5)
BMJ Open 11(10): e050116
Bardon AR, Dorward J, Sookrajh Y, Sayed F, Quame-Amaglo J, Pillay C, Feutz E, Ngobese H, Simoni JM, Sharma M, Cressey TR, Gandhi M, Lessells R, Moodley P, Naicker N, Naidoo K, Thomas K, Celum C, Abdool Karim S, Garrett N, Drain PK

Show complete publication list